TNGX Q3 2023 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+55.1% YoY

Gross Profit

$10M94.3% margin

Operating Income

-$26M-238.8% margin

Net Income

-$22M-207.4% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

-26.5%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$428M

Total Liabilities

$152M

Stockholders' Equity

$277M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$7M	+55.1%
Gross Profit	$10M	$6M	+77.5%
Operating Income	-$26M	-$30M	+14.4%
Net Income	-$22M	-$29M	+23.4%

Revenue Segments

Collaboration Revenue

$11M68%

License Revenue

$5M32%